Fungal infections, particularly those caused by resistant strains like Candida auris and Candida glabrata, pose a significant threat to global health. The widespread use of azole antifungals, such as fluconazole, has driven the emergence of multidrug-resistant strains, undermining the efficacy of existing treatments. These challenges necessitate the development of novel antifungal agents with enhanced activity and reduced resistance profiles. To address resistance mechanisms, we designed and synthesized hybrid molecules combining triazole and thiazolidine-2,4-dione (TZD) pharmacophores. This strategy leverages dual mechanisms of action: inhibiting fungal CYP51, a key enzyme in ergosterol biosynthesis, and disrupting fungal cell wall integrity. The structural versatility of hybrid molecules allows for targeted modifications to enhance antifungal potency, binding specificity, and pharmacokinetics. Using a stepwise synthetic approach, triazole-containing piperazine derivatives were first prepared and coupled with TZD-based carboxylic acids via optimized condensation reactions. The structures of the synthesized compounds were confirmed through advanced spectroscopic methods, including 1D/2D NMR and high-resolution mass spectrometry. The antifungal activity of these hybrids was evaluated in vitro against clinical and reference strains of Candida spp. and Aspergillus fumigatus. Among the synthesized compounds, 6a demonstrated notable activity against Candida parapsilosis (MIC 0.06 μg/mL), comparable to voriconazole. Compound 4b exhibited moderate activity against C. parapsilosis (MIC 1–2 μg/mL) and A. fumigatus (MIC 8 μg/mL). However, most compounds showed limited efficacy against highly resistant strains such as C. albicans 8R and C. krusei. This study highlights the potential of hybrid triazole-TZD molecules in overcoming resistance and improving antifungal efficacy. While promising, further optimization is required to broaden the spectrum of activity and enhance efficacy against multidrug-resistant pathogens. These findings contribute to the growing field of antifungal drug development, emphasizing hybrid approaches as a viable solution for combating fungal resistance.